S-1: NeOnc Technologies Faces Liquidity Concerns Amid Clinical Trials

NeOnc Technologies Holdings, Inc. reports significant losses and a going concern warning, while advancing multiple brain cancer drug candidates and securing recent financing.

Summary

• NeOnc Technologies Holdings, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for intracranial malignancies, including glioblastoma and metastatic brain cancers.
• The company has two lead product candidates: NEO100, administered intranasally for recurrent malignant glioma (Phase IIa ongoing) and malignant skull-based meningioma (Phase IIa ongoing), and NEO212, an oral drug for primary and secondary brain tumors (Phase I/II trial started in Q4 2023).
• NEO100 has Orphan Drug Designation and Fast Track status from the FDA for malignant glioma, and NEO212 has Orphan Drug Designation for glioma, brain metastases from breast cancer, and nasopharyngeal carcinoma.
• Preliminary Phase I results for intranasal NEO100 in recurrent glioblastoma patients showed 25% survival at 3 years, with 80% survival in IDH1 mutant patients beyond 24 months, exceeding historical benchmarks.
• The company acquired an intellectual property portfolio in 2025, including AI-driven drug discovery tools and magnetic 3D bioprinting technology, for approximately $3.5 million ($500,000 cash, $3.0 million in stock).
• NeOnc reported a net loss of $46,622,106 for the nine months ended September 30, 2025, significantly higher than $9,645,482 for the same period in 2024.
• The accumulated deficit reached $97,230,551 as of September 30, 2025, up from $50,608,445 at December 31, 2024.
• Revenue remains minimal, totaling $39,990 for the nine months ended September 30, 2025, primarily from humanitarian programs.
• The company's independent registered public accounting firm included an explanatory paragraph indicating substantial doubt about its ability to continue as a going concern.
• Recent financing activities include a private placement in January 2026 raising $10.6 million through the issuance of 1,475,249 shares of Common Stock and warrants to purchase an equal number of shares.
• An Equity Purchase Agreement with Mast Hill Fund, LP allows the company to sell up to $50 million of common shares, with $3,198,735 raised through September 30, 2025.
• A Line of Credit Agreement with HCWG for up to $10 million was established in October 2024, with no amounts borrowed through September 30, 2025.
• The company is in default on a $600,000 litigation settlement with a vendor (Fox Infused) and disputes an asserted $4 million payment obligation to Orient EuroPharma Co., Ltd. (OEP) following a terminated collaboration agreement.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a challenging period for NeOnc, marked by substantial financial losses and ongoing liquidity concerns, despite promising clinical trial data and recent capital raises. The 'going concern' warning and legal disputes weigh heavily on the sentiment.

Positives

• NEO100 has completed Phase I and is in Phase IIa clinical trials for recurrent malignant glioma and malignant skull-based meningioma, with promising preliminary survival data in IDH1 mutant patients.
• NEO100 received Fast Track status in 2016 and Orphan Drug Designation in 2011 from the FDA, offering potential regulatory and market exclusivity benefits.
• NEO212 has completed preclinical testing and received IND approval from the FDA, allowing it to proceed to Phase I/II clinical trials for primary and secondary brain tumors.
• NEO212 received Orphan Drug Designation for three indications: glioma, brain metastases from breast cancer, and nasopharyngeal carcinoma.
• The acquisition of AI-driven drug discovery tools and magnetic 3D bioprinting technology is expected to enhance and accelerate preclinical and clinical research.
• Preclinical studies suggest intranasal NEO100 may act as a delivery vehicle for other drugs, potentially for Parkinson's disease, and intra-arterial NEO100 may temporarily open the blood-brain barrier for other therapeutics.
• The company successfully raised approximately $10.6 million in a private placement in January 2026, enhancing liquidity and settling short-term debt.
• The expanded patient population for NEO100's Phase IIa trial (including Grade III IDH1,2 mutant astrocytomas) is projected to significantly expedite the trial process, with a readout potentially by the end of 2024, a year ahead of the original 2025 timeline.

Negatives

• The company has incurred significant operating losses, with a net loss of $46,622,106 for the nine months ended September 30, 2025, a substantial increase from $9,645,482 in the prior year period.
• The accumulated deficit has grown to $97,230,551 as of September 30, 2025, indicating a history of unprofitability.
• The company has not generated significant revenue from product sales and does not anticipate doing so for the foreseeable future, relying heavily on external funding.
• The independent auditor's report included an explanatory paragraph indicating substantial doubt about the company's ability to continue as a going concern.
• The company is in default on a $600,000 litigation settlement with Fox Infused, which could lead to further legal proceedings and operational disruptions.
• The company disputes a $4 million payment obligation to Orient EuroPharma Co., Ltd. (OEP) following a terminated collaboration, posing a risk of additional legal action and financial strain.
• Material weaknesses in internal control over financial reporting were identified, including controls over segregation of duties, risk assessment, information and communication, monitoring processes, financial controls, related party transactions, and information technology user access.
• The issuance of warrants in the recent private placement and the Equity Purchase Agreement could result in significant dilution for existing stockholders upon exercise.

Risks

• Substantial doubt exists about the company's ability to continue as a going concern due to recurring net losses and insufficient capital to fund operations for the next 12 months.
• The company will need substantial additional funding to support ongoing operations, advance product candidates, seek regulatory approvals, and build commercialization capabilities.
• Failure to raise additional funds or enter into collaboration agreements on acceptable terms could force delays, reductions, or termination of research and development programs or commercialization efforts.
• The process of clinical development is inherently uncertain, and there is no guarantee that product candidates will successfully complete trials, obtain regulatory approval, or be commercialized.
• The issuance of material amounts of Common Stock from warrant exercises will cause significant dilution to stockholders.
• Management has broad discretion over the use of proceeds from warrant exercises, and these proceeds may not be invested successfully.
• The company is dependent on third-party contract manufacturers for raw materials and finished products, and compliance with cGMP regulations is critical.
• Intellectual property protection is uncertain, and the issuance, scope, validity, enforceability, and commercial value of licensed patents are highly uncertain, potentially allowing competitors to commercialize similar products.
• The company faces intense competition in the global CNS treatment and brain tumor drug markets from large pharmaceutical companies, generics, and emerging therapies.
• Failure to comply with health and data protection laws and regulations (e.g., HIPAA, GDPR, CCPA) could lead to government enforcement actions, private litigation, and adverse publicity.
• Significant uncertainty exists regarding coverage and adequate reimbursement from third-party payors for any approved products, which could limit net revenue.
• Changes in healthcare laws and regulations, including cost-containment programs and drug pricing reforms, could adversely affect operations and profitability.
• The company is subject to Section 203 of the Delaware General Corporation Law, which may delay or prevent a change in control.
• The exclusive forum provision in the amended and restated bylaws may limit investors' ability to obtain a favorable judicial forum for disputes.

Future Outlook

The company expects to continue incurring significant and increasing expenses and operating losses as it advances product candidates through development, seeks regulatory approval, expands its intellectual property portfolio, and operates as a public company. It anticipates needing substantial additional funding and expects to finance operations through equity offerings, debt financings, or collaboration agreements. The readout for Phase II studies with respect to NEO100 is projected to be delivered by the end of 2024, advancing the original timeline by a full year from 2025. A Phase I clinical trial for intranasal NEO100 mixed with levodopa for Parkinson's disease is planned. The company also plans to further improve internal controls over financial reporting by enhancing access to accounting literature, identifying third-party professionals, considering additional staff, and migrating to Oracle NetSuite.

Management Comments

• "We believe this targeted enrollment of both Grade III and IV IDH1,2 mutants may significantly expedite our trial process and we project that the readout for our Phase II studies with respect to NEO100 could now be feasibly delivered by the end of 2024, advancing our original timeline by a full year from 2025."
• "We expect to continue to incur significant and increasing expenses and operating losses for the foreseeable future, as we advance our current and future product candidates through preclinical and clinical development, manufacture drug product and drug supply, seek regulatory approval for our current and future product candidates, maintain and expand our intellectual property portfolio, hire additional research and development and business personnel and operate as a public company."
• "We will not generate revenue from product sales unless and until we successfully complete clinical development and obtain regulatory approval for our product candidates."
• "Our ability to continue as a going concern is dependent upon our ability to raise additional funds and implement our strategies, such as executing additional licensing contracts."
• "Notwithstanding the assessment that our internal controls over financial reporting are not effective and that material weaknesses exist, we believe that we have employed supplementary procedures to ensure that the financial statements contained in this filing fairly present our financial position, results of operations, and cash flows for the reporting periods covered herein in all material respects."

Industry Context

StockSavvy.ai notes that NeOnc Technologies operates in the highly competitive and rapidly evolving global central nervous system (CNS) treatment and brain tumor drug markets. The company's focus on novel drug delivery methods, particularly intranasal administration to bypass the blood-brain barrier, addresses a critical challenge in treating brain malignancies. The acquisition of AI-driven drug discovery and 3D bioprinting platforms positions NeOnc to leverage advanced technologies, aligning with broader industry trends towards precision oncology and reduced reliance on animal models. However, the market is dominated by established players like Pfizer, Roche, and Merck, and new entrants face significant R&D investment, stringent regulatory hurdles, and intense competition from existing therapies (surgery, radiation, chemotherapy, immunotherapies, biologics, and gene therapies). The company's strategy to target specific patient populations (e.g., IDH1 mutant gliomas) and explore combination therapies is consistent with current industry efforts to improve outcomes in difficult-to-treat cancers.

Comparison to Industry Standards

• NEO100's preliminary Phase I results showing 21% radiographic responses and 44% six-month progression-free survival (PFS-6) in recurrent WHO Grade III/IV IDH1-mutant astrocytoma patients exceed historical benchmarks of <8% response rates and approximately 21-31% PFS-6 for recurrent high-grade gliomas in salvage therapy settings.
• The observed 25% survival rate at 3 years for glioblastoma patients in the Phase I trial is noteworthy, as recurrent glioblastoma patients typically have an average life expectancy of about six months, and 24-month survival is rare.
• The global brain tumor drug market is expected to grow at a CAGR of 9.8% to reach $4.6 billion by 2032, according to Fortune Business Insights, indicating a significant market opportunity for effective treatments.
• Radiation therapy still accounts for 38% of the brain cancer treatment market, with drug treatment lagging due to delivery inefficiencies, highlighting the potential impact of NeOnc's novel delivery methods if successful.
• The glioblastoma multiforme (GBM) drug market is expected to grow at 9.8% CAGR to $4.4 billion by 2023, driven by rising geriatric populations and increasing incidence, which NeOnc's GBM therapies aim to address.
• Competitors in the brain tumor space include Bristol Myers Squibb (Opdivo), Merck & Co., Inc. (Temozolomide), Roche (Avastin), Novocure (Optune device), AstraZeneca, Eli Lilly and Company, Pfizer, and Celldex Therapeutics, all engaged in various stages of research and commercialization.

Management Changes

Corporate Governance

Legal Proceedings

• The company is in default on a $600,000 litigation settlement with Fox Infused, LLC, stemming from a breach of contract claim related to an Intellectual Property License and Supply Agreement. Interest is accruing at the statutory rate on the unpaid balance since May 15, 2024.
• The company has a dispute with Orient EuroPharma Co., Ltd. (OEP) regarding a $4,000,000 settlement payment following the termination of a collaboration agreement. OEP believes the company is obligated to pay, while the company disputes this assertion, potentially leading to further legal action.

Related Party Transactions

• **AFH Holdings and Advisory, LLC (AFH)**: An advisory agreement was entered into on December 19, 2022, with AFH (Amir Heshmatpour is sole member). AFH assisted with public listing and fundraising. An amendment on July 12, 2024, provided for an upfront payment of $2,500,000 on the listing date and the remaining $8,828,565 in equal monthly installments for one year. AFH was paid a $500,000 fee for the amendment in 2024 and a total advisory fee of $11,328,565 in March 2025. AFH also acts as an exclusive advisor for financing and M&A for two years post-public offering.
• **University of Southern California (USC)**: The company has an exclusive license agreement with USC for its core technology. It pays an annual patent maintenance fee of $20,000 and earned royalties of 2% or 4% on Net Sales. An Amended and Restated Exclusive License Agreement in November 2023 addressed reporting obligations and financial deficiencies, including a $230,000 payment to cure unpaid sublicense fees (payment date extended to Sep 1, 2025, or 5 days post-offering). The company utilizes laboratory services from USC, incurring $461,000 and $326,000 in R&D costs in 2024 and 2023, respectively. As of Sep 30, 2025, $499,607 was owed to USC. In 2024, $1,377,096 owed to USC was converted into 114,758 common shares.
• **Accrued Compensation**: The company incurred $785,996 and $798,743 in compensation for its management team (all shareholders) in 2024 and 2023, respectively. As of Sep 30, 2025, $255,099 was accrued. In June 2024, $412,500 of accrued compensation was converted into 34,375 shares of common stock.
• **HCWG LLC**: In April 2023, the company entered into a non-interest bearing promissory note (Bridge Loan) with HCWG LLC (owned by Amir Heshmatpour, Dr. Thomas Chen, Keithly Garnett, and others). The Bridge Loan had a 50% original issue discount (OID) and a maximum borrowing of $10,000,000. In June 2024, the outstanding principal and interest of $11,748,464 was converted into 979,039 shares of common stock, terminating the loan. A Line of Credit Agreement for up to $10.0 million was entered into with HCWG in October 2024, bearing 10.0% interest, with no amounts borrowed through Sep 30, 2025. Warrants to purchase 312,500 shares at $12.00 were issued to HCWG in October 2024, with 162,500 shares issued upon cashless exercise in March 2025.
• **Executive Chairman Advances**: In February 2025, Amir Heshmatpour advanced approximately $300,000 to the company, carrying a 50% OID. The advance and 1x interest ($600,000 total) were repaid in March 2025 following the direct listing.
• **Orient EuroPharma Co., Ltd. (OEP)**: A collaboration and license agreement for NEO100 was terminated in February 2024, with a settlement agreement for a $4,000,000 payment by the company to OEP, contingent on the closing of an initial public offering. The company disputes this obligation following its direct listing.
• **Neucen Biomedical Co., Ltd. (NB)**: A license agreement for NEO212 was mutually terminated in June 2023. NB is partly owned by the spouse of a former director and Thomas Chen.

Stakeholder Impact

• **Shareholders**: Face significant dilution from the issuance of new shares and warrants in recent private placements and the Equity Purchase Agreement. The 'going concern' warning and substantial accumulated deficit pose a risk to investment value. However, successful clinical trial progression and potential market approvals could lead to significant upside.
• **Employees**: Increased employee headcount and compensation indicate growth in the workforce. Share-based compensation plans provide incentives, but vesting conditions and potential forfeitures (e.g., Patrick Walters' retirement) affect individual outcomes. The company's financial stability is crucial for job security.
• **Customers/Patients**: The development of novel treatments for aggressive brain cancers and Parkinson's disease offers potential new therapeutic options for patients with limited prognoses. The focus on intranasal delivery aims to improve efficacy and reduce side effects, enhancing patient quality of life.
• **Suppliers/Vendors**: The company's default on a $600,000 settlement with Fox Infused and dispute with OEP highlight payment risks for vendors and partners. This could impact future relationships and the company's ability to secure favorable terms.
• **Creditors**: The company's reliance on debt financing (e.g., convertible notes, line of credit) and its 'going concern' status indicate elevated risk for creditors. Recent capital raises have been used to settle some short-term debt, but overall financial health remains a concern.

Next Steps

• Complete Phase IIa clinical trials for intranasal NEO100 in recurrent malignant glioma and malignant skull-based meningioma patients, with a readout for NEO100 Phase II studies projected by end of 2024.
• Initiate a Phase I clinical trial for intranasal NEO100 mixed with levodopa for Parkinson's disease.
• Continue Phase I/II trial for oral NEO212 in patients with primary and secondary brain tumors.
• Advance preclinical studies for intranasal NEO212 for uncontrolled brain metastases, combination therapy with NEO100, and permeable delivery via intra-arterial NEO100.
• Obtain additional funding through public or private equity offerings, debt financings, or collaboration agreements to support ongoing operations and growth strategy.
• Remediate material weaknesses in internal control over financial reporting, including hiring additional financial personnel/consultants, implementing new accounting procedures, and migrating to Oracle NetSuite.
• Address outstanding litigation settlements with Fox Infused ($600,000 plus interest) and resolve the dispute with OEP regarding the $4,000,000 payment.

Key Dates

Recommendation

NeOnc Technologies presents a high-risk, high-reward profile. While the company is making significant progress in clinical trials for critical brain cancer treatments (NEO100, NEO212) and has secured recent financing, its substantial accumulated deficit, ongoing net losses, and the 'going concern' warning from auditors indicate significant financial instability. The potential for dilution from future capital raises and unresolved legal disputes add further uncertainty. The promising preliminary clinical data and strategic acquisition of AI/3D bioprinting technology offer long-term upside, but the immediate financial challenges and execution risks warrant a cautious 'hold' recommendation. Investors should monitor clinical trial readouts, progress on financial remediation, and resolution of legal matters before considering a more aggressive stance.

Keywords

Biopharmaceutical, Brain Cancer, Glioblastoma, Meningioma, NEO100, NEO212, Clinical Trials, Orphan Drug, Fast Track, Drug Delivery, Intranasal, AI Drug Discovery, 3D Bioprinting, SEC S-1, Liquidity, Going Concern, Dilution, Nasdaq